DCE-MRI for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment response for patients with pancreatic cancer that may be able to be removed by surgery (borderline resectable). Borderline resectable pancreatic cancer (BRPC) is a certain type of pancreatic cancer that involves the arteries or veins near the pancreas. With the right treatment before surgery, it can be removed (resected) successfully. An MRI (magnetic resonance imaging) scan creates clear images of the structures inside the body using a large magnet, radio waves, and a computer. DCE-MRI can be used to calculate the blood perfusion. Blood perfusion can show disease status. Using DCE-MRI as part of standard clinical evaluation may provide a more accurate treatment response assessment for patients with BRPC.
Who Is on the Research Team?
Harrison Kim, MBA, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with pancreatic cancer that might be removable by surgery (borderline resectable). Participants should be healthy enough for imaging and treatment, and not have conditions or allergies that would interfere with MRI scans or the study drugs.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Biospecimen Collection
- Computed Tomography
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Fluorouracil
- Gadolinium-Chelate
- Gemcitabine
- Irinotecan
- Leucovorin Calcium
- Nab-paclitaxel
- Oxaliplatin
- Point-of-care portable perfusion phantom (P4)
Trial Overview
The study is testing if using a special type of MRI scan (DCE-MRI) along with standard tests can better assess how well pre-surgery chemotherapy works in borderline resectable pancreatic cancer. Patients receive common chemo drugs and undergo advanced imaging.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Within two weeks prior to therapy initiation, patients receive gadolinium based contrast IV and undergo DCE-MRI. Patients then undergo standard of care treatment with gemcitabine and nab paclitaxel or fluorouracil, oxaliplatin, irinotecan and leucovorin, per the treating gastroenterology oncologist. Approximately 6 weeks after therapy initiation and again within 1 week prior to surgery, patients receive gadolinium based contrast IV and undergo DCE-MRI again. Patients undergo CT scan and blood sample collection throughout the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.